Road to 2025: DXB helping to treat kidney and respiratory disease
Stockhead TV
share
Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead.
Dimerix (ASX:DXB) is working to improve the lives of patients with inflammatory diseases, including both kidney and respiratory diseases. In this episode, Sarah Hughan covers DXB’s ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS), a second licensing deal and regulatory and ethics approval for their clinical trials.
Tune in to find out what to look out for in 2025.
This video was developed in collaboration with Dimerix, a Stockhead advertiser at the time of publishing.
The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.
